Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979492 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
A Phase 4 study of Sickle Cell Disease and Pregnancy Related, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06979492 is a Phase 4 study of Sickle Cell Disease and Pregnancy Related that is actively recruiting participants, run by Emory University. The registered enrollment target is 50 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06979492, a Phase 4 study of Sickle Cell Disease and Pregnancy Related, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications. Participants will be randomly assigned to repeated red blood cell transfusions or the standard of care. Participants will be on study for about 8-10 months (Pregnancy through 2 months post-partum).
Conditions Studied
Interventions
- BIOLOGICAL Prophylactic Transfusion Intervention group: Transfusion
- OTHER Control group
Study Locations (1)
Georgia
- Grady Health System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979492
The ClinicalTrials.gov registry entry for NCT06979492 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Prophylactic Transfusion Intervention group: Transfusion is the first listed.
NCT06979492 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06979492 about?
NCT06979492 is a clinical study titled "Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease". The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-relate...
What is the current status of trial NCT06979492?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2026-04. Estimated completion is 2028-05.
What conditions does trial NCT06979492 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Pregnancy Related.
What interventions are being tested in trial NCT06979492?
The interventions under investigation include: Prophylactic Transfusion Intervention group: Transfusion (BIOLOGICAL), Control group (OTHER).
Who is sponsoring clinical trial NCT06979492?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979492 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
RECRUITING · Phase 4
-
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
RECRUITING · Phase 4
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.